Background Bcl-2 family members play an important role in the development of malignant
lymphoma and can induce drug resistance in anticancer treatment. The development of …

Hematopoietic malignancies frequently are characterized by defects in apoptosis signaling.
This renders the malignant cells resistant to endogenous apoptotic stimuli, as well as …

Circumvention of apoptotic machinery is one of the distinctive properties of carcinogenesis.
Extensively established key effectors of such apoptotic bypass mechanisms, the …

B‐cell lymphoma 2 (Bcl‐2) is a regulator protein involved in apoptosis. In the past few
decades, this protein has been demonstrated to have high efficacy in cancer therapy, and …

Disruption of the physiologic balance between cell proliferation and cell death is an
important step of cancer development. Increased resistance to apoptosis is a key oncogenic …

Antiapoptotic BCL2 proteins play a major role in tumor cell survival. Hence, BCL2 inhibitors
have been developed as direct inducers of apoptosis. ABT-199 (venetoclax) received …

Malignant cells routinely violate cellular checkpoints that should initiate cell death in normal
cells by triggering pro‐apoptotic members of the BCL‐2 family of proteins. To escape such …

The specific targeting of diseases, particularly cancer, is a primary aim in drug development,
as specificity reduces unwelcome effects on healthy tissue and increases drug efficacy at the …

A remarkable characteristic of majority of cancer cells is that, they fail to undergo apoptosis,
which in turn confers them a survival advantage over normal cells. Targeted cancer therapy …

A balance of Bcl-2 family proteins dictates cell survival or death, as the interactions between
these proteins regulate mitochondrial apoptotic signaling pathways. However, cancer cells …